Yes I agree. Fact is, the stock would have moved significantly...

Yes I agree. Fact is, the stock would have moved significantly and retained its value on the back of Hologic if there was ongoing revenues guaranteed. Because there isn't at this stage, it provided an opportunity for CR punters to get out high.

Also, the company never providing guidance or updates on revenue is a laugh to me. From the highlighted commercial update webinar, they provided an update on revenues for Viradx which spurred the ramp to the .10c mark again for CR buyers to sell out for a pretty big gain. What followed? PVM dump.








The instos know there is always a typical sell off in retail post CR announcement. If anyone recalls there was an AGM announcement post CR which had a correction issued regarding sales of product date being incorrect. This further spurred the sell to .06 mark prior to the commercial update.

So my questions previously to IR and HO about the updated on sales figures given the expansion of the product had actually occurred previously, they just haven't anymore as their baseline last year of $700K in sales may not be hitting the mark this time around. It was easy to put the above in the announcement since there was no prior sales.....